{"entity":{"id":"nct05315167","kind":"trial","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of PRJ1-3024 in advanced solid tumours, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.","summary":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05315167 by Zhuhai Yufan Biotechnologies Co., Ltd, with 267 participants planned, started 2022-05-30 and due to reach its primary completion in 2027-05-15. Interventions recorded: PRJ1-3024.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05315167","url":"https://clinicaltrials.gov/study/NCT05315167"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05315167","phase":"1/2","setting":"A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Prime Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","sponsor":"Zhuhai Yufan Biotechnologies Co., Ltd","enrolled":267,"outcomes":[]},"route":"/trials/nct05315167/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/"}]}}